Haematological cancer: Anti-BCMA CAR T cells show promise in MM.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. [Structural evolution and prospect of chimeric antigen receptor T cell (CAR-T cell)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020
   Article
2. Infusion of chimeric antigen receptor T cells against dual targets of CD19 and B-cell maturation antigen for the treatment of refractory multiple myeloma.The Journal of international medical research · 2020
   Observational
3. Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment.Frontiers in oncology · 2020
   Review
4. CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth.Cancers · 2018
   Article
5. The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.Journal of Cancer · 2017
   Review

Corrections and comments

• Comment on
  T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.2016

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as